Abstract
Treatment for ST-elevation myocardial infarction (MI) has advanced rapidly in the last few years with improvements in early fibrinolytic therapy, primary percutaneous revascularization, and use of potent platelet glycoprotein IIb/IIIa inhibitors. It is now obvious that establishing epicardial patency after myocardial infarction is not synonymous with tissue-level perfusion. Techniques and therapies are now available that measure true tissue-level perfusion and that may improve tissue-level perfusion after myocardial infarction.
MeSH terms
-
Abciximab
-
Animals
-
Antibodies, Monoclonal / therapeutic use
-
Coronary Thrombosis / physiopathology
-
Heart / physiopathology
-
Humans
-
Immunoglobulin Fab Fragments / therapeutic use
-
Myocardial Infarction / drug therapy*
-
Myocardial Infarction / physiopathology*
-
Myocardial Reperfusion Injury / physiopathology
-
Myocardial Reperfusion*
-
Platelet Aggregation / physiology
-
Platelet Aggregation Inhibitors / therapeutic use
-
Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use
-
Regional Blood Flow
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Abciximab